Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET

被引：71
作者：
Contractor, Kaiyumars B. [1 ]
Aboagye, Eric O. [1 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Ctr Clin Sci, Dept Oncol, London W12 0NN, England
来源：
JOURNAL OF NUCLEAR MEDICINE | 2009年 / 50卷
基金：
英国医学研究理事会;
关键词：
F-18-FDG PET; cytostatic treatment; cytoreductive therapy; response monitoring; imatinib mesylate; POSITRON-EMISSION-TOMOGRAPHY; GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE INHIBITOR; IMATINIB MESYLATE THERAPY; CELL LUNG-CANCER; PHASE-I TRIAL; BREAST-CANCER; FDG-PET; EARLY PREDICTION; COLORECTAL-CANCER;
D O I：
10.2967/jnumed.108.057273
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
F-18-FDG PET and, more recently, PET/CT have been established as response biomarkers for monitoring cytotoxic or cytoreductive cancer therapies. With the advent of targeted cancer therapies, which are predominantly cytostatic, F-18-FDG PET is increasingly being used to monitor the therapeutic response to these agents as well. The impressive outcome of F-18-FDG PET studies in patients with gastrointestinal stromal tumors treated with imatinib mesylate brought to the forefront the use of this biomarker for assessing the response to targeted therapies. The use of F-18-FDG PET for this purpose has practical challenges, including quantitative analysis and timing of scans. This review provides a summary of clinical studies of targeted therapies done to date with F-18-FDG PET and provides guidance on practical issues to ensure the optimal interpretation of imaging data in drug development and for patient care.
引用
收藏
页码：97S / 105S
页数：9
相关论文
共 91 条
[81]   Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer [J].
Sunaga, Noriaki ;
Oriuchi, Noboru ;
Kaira, Kyoichi ;
Yanagitani, Noriko ;
Tomizawa, Yoshio ;
Hisada, Takeshi ;
Ishizuka, Tamotsu ;
Endo, Keigo ;
Mori, Masatomo .
LUNG CANCER, 2008, 59 (02) :203-210
[82]   Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms [J].
Tarn, Chi ;
Skorobogatko, Yuliya V. ;
Taguchi, Takahiro ;
Eisenberg, Burton ;
von Mehren, Margaret ;
Godwin, Andrew K. .
CANCER RESEARCH, 2006, 66 (10) :5477-5486
[83]   Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer [J].
Thomas, GV ;
Tran, C ;
Mellinghoff, IK ;
Welsbie, DS ;
Chan, E ;
Fueger, B ;
Czernin, J ;
Sawyers, CL .
NATURE MEDICINE, 2006, 12 (01) :122-127
[84]   Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs) [J].
Van den Abbeele, AD ;
Badawi, RD .
EUROPEAN JOURNAL OF CANCER, 2002, 38 :S60-S65
[85]   The lessons of GIST - PET and PET/CT: A new paradigm for imaging [J].
Van den Abbeele, Annick D. .
ONCOLOGIST, 2008, 13 :8-13
[86]   Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study [J].
van Oosterom, AT ;
Judson, I ;
Verweij, J ;
Stroobants, S ;
di Paola, ED ;
Dimitrijevic, S ;
Martens, M ;
Webb, A ;
Sciot, R ;
Van Glabbeke, M ;
Silberman, S ;
Nielsen, OS .
LANCET, 2001, 358 (9291) :1421-1423
[87]   CARBOHYDRATE METABOLISM IN CANCER CELLS AND MOLECULAR CORRELATION CONCEPT [J].
WEBER, G .
NATURWISSENSCHAFTEN, 1968, 55 (09) :418-&
[88]  
Weber WA, 1999, J NUCL MED, V40, P1771
[89]   Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma [J].
Wei, Liu Hua ;
Su, Helen ;
Hildebrandt, Isabel J. ;
Phelps, Michael E. ;
Czernin, Johannes ;
Weber, Wolfgang A. .
CLINICAL CANCER RESEARCH, 2008, 14 (11) :3416-3426
[90]   Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies [J].
Workman, Paul ;
Aboagye, Eric O. ;
Chung, Yuen-Li ;
Griffiths, John R. ;
Hart, Rachel ;
Leach, Martin O. ;
Maxwell, Ross J. ;
McSheehy, Paul M. J. ;
Price, Pat M. ;
Zweit, Jamal .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (09) :580-598
12345678910